Maas Arthur C P, Wyatt Christina M, Green Cynthia L, Wagner Galen S, Trollinger Kathleen M, Pope James E, Langer Anatoly, Armstrong Paul W, Califf Robert M, Simoons Maarten L, Krucoff Mitchell W
Duke University Medical Center, Durham, NC, USA.
Am Heart J. 2004 Apr;147(4):698-704. doi: 10.1016/j.ahj.2003.08.014.
Clinical descriptors and ST-segment recovery variables hold prognostic information for clinical outcome after thrombolysis for acute myocardial infarction (MI). We sought to define the incremental prognostic value of continuous 12-lead ST-segment monitoring variables to clinical risk descriptors identified by the Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries (GUSTO-I) trial 30-day mortality analysis.
Of 1,777 patients enrolled in continuous ST-segment substudies from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-9), GUSTO-I, Duke University Clinical Cardiology Study (DUCCS-II), Integrilin to manage Platelet Aggregation to Combat Thrombus in Acute Myocardial Infarction (IMPACT-AMI), Promotion of Reperfusion by Inhibition of Thrombin During Myocardial Infarction Evolution (PRIME), and Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trials, 825 patients qualified for assessment of time to recovery. ST recovery variables analyzed were time to stable ST-recovery and late ST elevation. Patients who were at low clinical risk (n = 261) had no high-risk descriptors, and patients at high clinical risk (n = 564) had at least 1 of these high-risk descriptors: age >or=70 years, systolic blood pressure <or=110 mm Hg, heart rate >or=90 beats/min, anterior MI, or previous MI. High (n = 90), moderate (n = 318), and low (n =417) ST-risk groups were defined by the presence of both slow ST recovery and late ST elevation, one or the other, or neither, respectively. End points analyzed were inhospital death and combined death, reinfarction, or congestive heart failure.
There was a trend toward increased mortality rate in the high-clinical/high-ST-risk group. For the composite end point, ST subgrouping resulted in significant event stratification in both patients at low and high clinical risk. In multivariable analysis, age and heart rate were independent predictors of both mortality and the composite end point. Late ST elevation added incremental prognostic information.
Age, heart rate, and late ST elevation are powerful, independent predictors of adverse clinical outcome. Continuous monitoring allows noninvasive assessment of the response to therapy. Consequently, this technique will enhance the potential to risk-stratify individual patients in a real-time setting.
临床描述符和ST段恢复变量对急性心肌梗死(MI)溶栓后的临床结局具有预后信息。我们试图确定连续12导联ST段监测变量对由全球应用链激酶和组织型纤溶酶原激活剂(阿替普酶)治疗闭塞冠状动脉(GUSTO-I)试验30天死亡率分析所确定的临床风险描述符的增量预后价值。
在心肌梗死溶栓与血管成形术(TAMI-9)、GUSTO-I、杜克大学临床心脏病学研究(DUCCS-II)、心肌梗死中使用依替巴肽抑制血小板聚集以对抗血栓形成(IMPACT-AMI)、心肌梗死演变过程中通过抑制凝血酶促进再灌注(PRIME)以及心肌梗死中血小板聚集受体拮抗剂剂量研究和再灌注获益(PARADIGM)试验的连续ST段亚研究中纳入的1777例患者中,825例患者符合恢复时间评估标准。分析的ST恢复变量为达到稳定ST恢复的时间和晚期ST段抬高。临床风险低的患者(n = 261)没有高危描述符,临床风险高的患者(n = 564)至少有以下高危描述符之一:年龄≥70岁、收缩压≤110 mmHg、心率≥90次/分钟、前壁心肌梗死或既往心肌梗死。高(n = 90)、中(n = 318)和低(n = 417)ST风险组分别由存在缓慢ST恢复和晚期ST段抬高、二者之一或二者均无来定义。分析的终点为住院死亡以及死亡、再梗死或充血性心力衰竭的复合终点。
高临床/高ST风险组的死亡率有增加趋势。对于复合终点,ST亚组分析在临床风险低和高的患者中均导致了显著的事件分层。在多变量分析中,年龄和心率是死亡率和复合终点的独立预测因素。晚期ST段抬高增加了增量预后信息。
年龄、心率和晚期ST段抬高是不良临床结局的有力独立预测因素。连续监测可对治疗反应进行无创评估。因此,该技术将增强在实时环境中对个体患者进行风险分层的潜力。